4 Friedman S L. Liver fibrosis-- from bench to bedside. J Hepatol, 2003, 38: S38-53
[2]
5 Smith J O, Sterling R K. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther, 2009
[3]
6 Beretta L. Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarkerdiscovery. Cancer Lett, 2009
[4]
7 Ong S E, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol, 2005, 1: 252-262？？
[5]
8 Tao W A, Aebersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr Opin Biotechnol, 2003,14: 110-118？？
[6]
9 Wu S, Kaiser N K, Meng D, et al. Increased protein identification capabilities through novel tandem MS calibration strategies. J ProteomeRes, 2005, 4: 1434-1441
[7]
10 Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol, 1991, 13: 372-374？？
[8]
11 Beardsley R L, Reilly J P. Optimization of guanidination procedures for MALDI mass mapping. Anal Chem, 2002, 74: 1884-1890？？
[9]
12 Ji C, Guo N, Li L. Differential dimethyl labeling of N-termini of peptides after guanidination for proteome analysis. J Proteome Res, 2005,4: 2099-2108？？
[10]
13 Jia N, Liu X, Wen J, et al. A proteomic method for analysis of CYP450s protein expression changes in carbon tetrachloride induced male ratliver microsomes. Toxicology, 2007, 237: 1-11？？
[11]
14 Meneses-Lorente G, Watt A, Salim K, et al. Identification of early proteomic markers for hepatic steatosis. Chem Res Toxicol, 2006, 19: 986-998？？
[12]
2 Lok A S, McMahon B J. Chronic hepatitis B. Hepatology, 2001, 34: 1225-1241？？
[13]
15 Nedelkov D, Kiernan U A, Niederkofler E E, et al. Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA, 2005, 102:10852-10857？？
[14]
3 Afdhal N H, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol, 2004, 99: 1160-1174？？
[15]
16 Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.Hepatology, 2005, 41: 1376-1382？？
[16]
17 Rockey D C, Bissell D M. Noninvasive measures of liver fibrosis. Hepatology, 2006, 43: S113-S120？？
[17]
18 Everley P A, Bakalarski C E, Elias J E, et al. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracyinstrumentation. J Proteome Res, 2006, 5: 1224-1231？？
[18]
19 Koumenis I L, Vestal M L, Yergey A L, et al. Quantitation of metal isotope ratios by laser desorption time-of-flight mass spectrometry.Anal Chem, 1995, 67: 4557-4564？？
[19]
20 Noga M J, Asperger A, Silberring J. N-terminal H3/D3-acetylation for improved high-throughput peptide sequencing by matrix-assisted laserdesorption/ionization mass spectrometry with a time-of-flight/time-of-flight analyzer. Rapid Commun Mass Spectrom, 2006, 20: 1823-1827？？
[20]
21 Zappacosta F, Annan R S. N-terminal isotope tagging strategy for quantitative proteomics: results-driven analysis of protein abundancechanges. Anal Chem, 2004, 76: 6618-6627？？
[21]
22 Burt A D. C L Oakley Lecture. Cellular and molecular aspects of hepatic fibrosis. J Pathol, 1993, 170: 105-114？？
[22]
23 Azuma T, Koths K, Flanagan L, et al. Gelsolin in complex with phosphatidylinositol 4,5-bisphosphate inhibits caspase-3 and -9 to retardapoptotic progression. J Biol Chem, 2000, 275: 3761-3766
[23]
24 Neubauer K, Baruch Y, Lindhorst A, et al. Gelsolin gene expression is upregulated in damaged rat and human livers withinnon-parenchymal cells and not in hepatocytes. Histochem Cell Biol, 2003, 120: 265-275？？
[24]
25 Suhler E, Lin W, Yin H L, et al. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, andmyonecrosis. Crit Care Med, 1997, 25: 594-598？？
[25]
26 Attallah A M, Zahran F, Ismail H, et al. Immunochemical identification and detection of serum fibronectin in liver fibrosis patients withchronic hepatitis C. J Immunoassay Immunochem, 2007, 28: 331-342？？
[26]
27 Grieco A, Matera A, Di Rocco P, et al. Plasma levels of fibronectin in patients with chronic viral and alcoholic liver disease.Hepatogastroenterology, 1998, 45: 1731-1736
[27]
28 Perez Blanco F J, Rodriguez Cuartero A, Nunez Carril J, et al. Haptoglobin and hemopexin in the chronic hepatopathies. Rev Esp EnfermApar Dig, 1982, 62: 20-24
[28]
29 Poli V, Silengo L, Altruda F, et al. The analysis of the human hemopexin promoter defines a new class of liver-specific genes. NucleicAcids Res, 1989, 17: 9351-9365
[29]
30 Ratra R, Kar-Roy A, Lal S K. The ORF3 protein of hepatitis E virus interacts with hemopexin by means of its 26 amino acid N-terminalhydrophobic domain II. Biochemistry, 2008, 47: 1957-1969？？
[30]
31 Koukoulis G K, Shen J, Virtanen I, et al. Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis. Hum Pathol, 2001, 32: 1356-1362？？
[31]
32 Yamada S, Kobayashi J, Murawaki Y, et al. Collagen-binding activity of plasma vitronectin in chronic liver disease. Clin Chim Acta, 1996,252: 95-103？？
[32]
33 Fan C, Stendahl U, Stjernberg N, et al. Association between orosomucoid types and cancer. Oncology, 1995, 52: 498-500？？
[33]
34 Sorensson J, Matejka G L, Ohlson M, et al. Human endothelial cells produce orosomucoid, an important component of the capillary barrier.Am J Physiol, 1999, 276: H530-534
[34]
35 Lovat L B, Persey M R, Madhoo S, et al. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut, 1998, 42: 727-734？？
[35]
36 Levo Y, Shalit M, Tur-Kaspa R. Serum amyloid P-component as a marker of liver disease. Am J Gastroenterol, 1982, 77: 427-430
[36]
37 Munthe-Fog L, Hummelshoj T, Honore C, et al. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med,2009, 360: 2637-2644？？
[37]
39 Giannelli G, Antonaci S. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol,2005, 20: 939-944
[38]
40 Mehta A S, Long R E, Comunale M A, et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis Cvirus-infected individuals with fibrosis and cirrhosis. J Virol, 2008, 82: 1259-1270？？
[39]
41 Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosisin patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 2006, 6: 6？？
[40]
42 Gobel T, Vorderwulbecke S, Hauck K, et al. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma inchronic hepatitis C serum samples. World J Gastroenterol, 2006, 12: 7604-7612
[41]
43 West R B, Harvell J, Linn S C, et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol,2004, 28: 1063-1069？？
[42]
44 Otogawa K, Kinoshita K, Fujii H, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation,and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol, 2007,170: 967-980？？
[43]
45 Poon T C, Hui A Y, Chan H L, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomicfingerprinting: a pilot study. Clin Chem, 2005, 51: 328-335？？
[44]
46 Arteel G E. "HOPE" for the liver? Mechanistic insight into the role of the renin-angiotensin system in hepatic fibrosis. Hepatology, 2004, 40:263-265？？
[45]
47 Xiao F, Wei H, Song S, et al. Polymorphisms in the promoter region of the angiotensinogen gene are associated with liver cirrhosis inpatients with chronic hepatitis B. J Gastroenterol Hepatol, 2006, 21: 1488-1491
[46]
48 Schiavon L L, Schiavon J L, Filho R J, et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients withchronic hepatitis C virus infection. Hepatology, 2007, 46: 307-314？？
[47]
49 Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virusrelated liver disease. Am J Gastroenterol, 2006, 101: 2537-2545
[48]
50 Lebensztejn D M, Skiba E, Sobaniec-Lotowska M, et al. A simple noninvasive index (APRI) predicts advanced liver fibrosis in childrenwith chronic hepatitis B. Hepatology, 2005, 41: 1434-1435？？
[49]
51 Murata C, Watanabe T, Furuya H, et al. Aldehyde dehydrogenase 2 and beta3-adrenergic receptor gene polymorphisms: their associationwith elevated liver enzymes and metabolic syndrome. Metabolism, 2003, 52: 1096-1101？？
[50]
52 Enomoto N, Takase S, Takada N, et al. Alcoholic liver disease in heterozygotes of mutant and normal aldehyde dehydrogenase-2 genes.Hepatology, 1991, 13: 1071-1075？？
[51]
53 Ferre N, Marsillach J, Camps J, et al. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. ClinChim Acta, 2005, 361: 206-210
[52]
54 Shirai R, Hirano F, Ohkura N, et al. Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators ofacute-phase response. Biochem Biophys Res Commun, 2009, 382: 776-779？？
[53]
55 Heo S H, Lee S J, Ryoo H M, et al. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectinaffinity chromatography and LC-MS/MS. Proteomics, 2007, 7: 4292-4302？？
[54]
56 De Sa S V, Correa-Giannella M L, Machado M C, et al. Serpin peptidase inhibitor clade A member 1 as a potential marker for malignancyin insulinomas. Clin Cancer Res, 2007, 13: 5322-5330？？
[55]
57 Sathe S, Sakata M, Beaton A R, et al. Identification, origins and the diurnal role of the principal serine protease inhibitors in human tearfluid. Curr Eye Res, 1998, 17: 348-362？？
59 Zhou M, Shen D, Head J E, et al. Ocular clusterin expression in von Hippel-Lindau disease. Mol Vis, 2007, 13: 2129-2136
[58]
60 Rodriguez-Pineiro A M, de la Cadena M P, Lopez-Saco A, et al. Differential expression of serum clusterin isoforms in colorectal cancer.Mol Cell Proteomics, 2006, 5: 1647-1657？？ 61 Chen X, Halberg R B, Ehrhardt W M, et al. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci USA,2003, 100: 9530-9535？？
[59]
62 Kang Y K, Hong S W, Lee H, et al. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol, 2004, 35: 1340-1346？？
[60]
63 Meistermann H, Norris J L, Aerni H R, et al. Biomarker discovery by imaging mass spectrometry: transthyretin is a biomarker forgentamicin-induced nephrotoxicity in rat. Mol Cell Proteomics, 2006, 5: 1876-1886？？
[61]
64 Biroccio A, Del Boccio P, Panella M, et al. Differential post-translational modifications of transthyretin in Alzheimer''s disease: a study ofthe cerebral spinal fluid. Proteomics, 2006, 6: 2305-2313？？
[62]
65 Barcelo-Batllori S, Kalko S G, Esteban Y, et al. Integration of DIGE and bioinformatics analyses reveals a role of the antiobesity agenttungstate in redox and energy homeostasis pathways in brown adipose tissue. Mol Cell Proteomics, 2008, 7: 378-393
[63]
66 Saile B, Ramadori G. Inflammation, damage repair and liver fibrosis-- role of cytokines and different cell types. Z Gastroenterol, 2007, 45: 77-86？？
[64]
67 Kershenobich S D, Weissbrod A B. Liver fibrosis and inflammation: a review. Ann Hepatol, 2003, 2: 159-163
[65]
38 Le Y, Lee S H, Kon O L, et al. Human L-ficolin: plasma levels, sugar specificity, and assignment of its lectin activity to the fibrinogen-like(FBG) domain. FEBS Lett, 1998, 425: 367-370？？
[66]
68 Yip T T, Cho W C, Cheng W W, et al. Application of ProteinChip array profiling in serum biomarker discovery for patients suffering fromsevere acute respiratory syndrome. Methods Mol Biol, 2007, 382: 313-331？？
[67]
69 Spisak S, Tulassay Z, Molnar B, et al. Protein microchips in biomedicine and biomarker discovery. Electrophoresis, 2007, 28: 4261-4273？？
[68]
70 Zhang G, Terry A V Jr, Bartlett M G. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine,risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. Rapid Commun Mass Spectrom, 2007, 21: 920-928
[69]
71 Boersema P J, Raijmakers R, Lemeer S, et al. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc,2009, 4: 484-494？？
[70]
1 Lee W M. Hepatitis B virus infection. N Engl J Med, 1997, 337: 1733-1745？？
